Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds
Jorge Berlanga Acosta(Centro de Ingeniería Genética y Biotecnología), José I Fernández‐Montequín(Instituto de Gastroenterología), Neobalis Franco, Ernesto López‐Morales(Centro de Ingeniería Genética y Biotecnología), José Suárez Alba(Centro de Ingeniería Genética y Biotecnología), Luís Herrera(Orlando Health), Gerardo Guillén(Hunan City University), William Savigne, Amaurys del Río, Pedro López‐Saura(United States Nuclear Regulatory Commission), Calixto Valdez
Cited by 77
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134